-
ASPHER Statement: Déjà vu? Planning for the Covid-19 Third Wave and Planning for the Winter 2021-22.International Journal of Public Health 2021
Topics: COVID-19; Humans; Seasons
PubMed: 34497482
DOI: 10.3389/ijph.2021.1604361 -
BJOG : An International Journal of... Jan 2022
Topics: COVID-19; Civil Defense; Climate Change; Communicable Disease Control; Communicable Diseases, Emerging; Female; Health Services Needs and Demand; Humans; Infectious Disease Transmission, Vertical; Pandemics; Pregnancy; Pregnancy Complications, Infectious; Public Health; SARS-CoV-2; Travel; Travel-Related Illness
PubMed: 34379870
DOI: 10.1111/1471-0528.16859 -
Brain Stimulation 2018Epileptic patients sometimes report experiential phenomena related to a previous dream they had during seizures or electrical brain stimulation (EBS). This has been...
BACKGROUND
Epileptic patients sometimes report experiential phenomena related to a previous dream they had during seizures or electrical brain stimulation (EBS). This has been alluded to in the literature as "déjà-rêvé" ("already dreamed"). However, there is no neuroscientific evidence to support its existence and this concept is commonly mixed up with déjà-vu. We hypothesized that déjà-rêvé would be a specific entity, i.e., different from other experiential phenomena reported in epileptic patients, induced by EBS of specific brain areas.
METHODS
We collected all experiential phenomena related to dreams induced by electrical brain stimulations (EBS) in our epileptic patients (2003-2015) and in a review of the literature. The content of these déjà-rêvé and the location of EBS were analyzed.
RESULTS
We collected 7 déjà-rêvé in our database and 35 from the literature, which corresponds to an estimated prevalence of 0.3‰ of all EBS-inducing déjà-rêvé. Déjà-rêvé is a generic term for three distinct entities: it can be the recollection of a specific dream ("episodic-like"), reminiscence of a vague dream ("familiarity-like") or experiences in which the subject feels like they are dreaming (literally "a dreamy state"). EBS-inducing "episodic-like" and "familiarity-like" déjà-rêvé were mostly located in the medial temporal lobes. "Dreamy states" were induced by less specific EBS areas although still related to the temporal lobes.
CONCLUSIONS
This study demonstrates that déjà-rêvé is a heterogeneous entity that is different from déjà-vu, the historical "dreamy state" definition and other experiential phenomena. This may be relevant for clinical practice as it points to temporal lobe dysfunction and could be valuable for studying the neural substrates of dreams.
Topics: Adolescent; Adult; Child; Deep Brain Stimulation; Dreams; Emotions; Epilepsy, Temporal Lobe; Female; Humans; Male; Memory; Mental Recall; Recognition, Psychology; Temporal Lobe; Young Adult
PubMed: 29530448
DOI: 10.1016/j.brs.2018.02.016 -
Empirical Software Engineering 2022The paper introduces a fundamental technological problem with collecting high-speed eye tracking data while studying software engineering tasks in an integrated...
Deja Vu: semantics-aware recording and replay of high-speed eye tracking and interaction data to support cognitive studies of software engineering tasks-methodology and analyses.
The paper introduces a fundamental technological problem with collecting high-speed eye tracking data while studying software engineering tasks in an integrated development environment. The use of eye trackers is quickly becoming an important means to study software developers and how they comprehend source code and locate bugs. High quality eye trackers can record upwards of 120 to 300 gaze points per second. However, it is not always possible to map each of these points to a line and column position in a source code file (in the presence of scrolling and file switching) in real time at data rates over 60 gaze points per second without data loss. Unfortunately, higher data rates are more desirable as they allow for finer granularity and more accurate study analyses. To alleviate this technological problem, a novel method for eye tracking data collection is presented. Instead of performing gaze analysis in real time, all telemetry (keystrokes, mouse movements, and eye tracker output) data during a study is recorded as it happens. Sessions are then replayed at a much slower speed allowing for ample time to map gaze point positions to the appropriate file, line, and column to perform additional analysis. A description of the method and corresponding tool, Deja Vu, is presented. An evaluation of the method and tool is conducted using three different eye trackers running at four different speeds (60 Hz, 120 Hz, 150 Hz, and 300 Hz). This timing evaluation is performed in Visual Studio, Eclipse, and Atom IDEs. Results show that Deja Vu can playback 100% of the data recordings, correctly mapping the gaze to corresponding elements, making it a well-founded and suitable post processing step for future eye tracking studies in software engineering. Finally, a proof of concept replication analysis of four tasks from two previous studies is performed. Due to using the Deja Vu approach, this replication resulted in richer collected data and improved on the number of distinct syntactic categories that gaze was mapped on in the code.
PubMed: 36159896
DOI: 10.1007/s10664-022-10209-3 -
Tumour Biology : the Journal of the... Jun 2017From the application of Coley's toxin in the early 1900s to the present clinical trials using immune checkpoint regulatory inhibitors, the history of cancer... (Review)
Review
From the application of Coley's toxin in the early 1900s to the present clinical trials using immune checkpoint regulatory inhibitors, the history of cancer immunotherapy has consisted of extremely high levels of enthusiasm after anecdotal case reports of enormous success, followed by decreasing levels of enthusiasm as the results of controlled clinical trials are available. In this review, this pattern will be documented for the various immunotherapeutic approaches over the years. The sole exception being vaccination against cancer causing viruses, which have already prevented thousands of cancers. We can only hope that the present high level of enthusiasm for the use of immune stimulation by removal of blocks to cancer immunity will be more productive than the incremental improvements using previous immunotherapies.
Topics: Cancer Vaccines; Genes, cdc; Humans; Immunotherapy; Neoplasms
PubMed: 28639883
DOI: 10.1177/1010428317707764 -
Atherosclerosis Aug 2019
Topics: Humans; Ischemia; Plaque, Atherosclerotic; White Matter
PubMed: 31213292
DOI: 10.1016/j.atherosclerosis.2019.05.021 -
Annals of Internal Medicine Jun 2021Klompas and colleagues report an investigation of a SARS-CoV-2 cluster in an acute care hospital with transmission between patients and staff. The editorialists remind...
Klompas and colleagues report an investigation of a SARS-CoV-2 cluster in an acute care hospital with transmission between patients and staff. The editorialists remind us of the need to reinforce and reeducate to improve practice of and adherence to important strategies that protect the entire health care ecosystem.
Topics: COVID-19; Delivery of Health Care; Hospitals; Humans; SARS-CoV-2
PubMed: 33556269
DOI: 10.7326/M21-0526 -
Behavioral Sciences (Basel, Switzerland) Aug 2017The Inventory Déjà Vu Experiences Assessment (IDEA) is the only screening instrument proposed to evaluate the Déjà vu (DV) experience. Here, we intended to validate...
Validation Study of Italian Version of Inventory for Déjà Vu Experiences Assessment (I-IDEA): A Screening Tool to Detect Déjà Vu Phenomenon in Italian Healthy Individuals.
The Inventory Déjà Vu Experiences Assessment (IDEA) is the only screening instrument proposed to evaluate the Déjà vu (DV) experience. Here, we intended to validate the Italian version of IDEA (I-IDEA) and at the same time to investigate the incidence and subjective qualities of the DV phenomenon in healthy Italian adult individuals on basis of an Italian multicentre observational study. In this study, we report normative data on the I-IDEA, collected on a sample of 542 Italian healthy subjects aging between 18-70 years (average age: 40) with a formal educational from 1-19 years. From September 2013 to March 2016, we recruited 542 healthy volunteers from 10 outpatient neurological clinics in Italy. All participants (i.e., family members of neurological patients enrolled, medical students, physicians) had no neurological or psychiatric illness and gave their informed consent to participate in the study. All subjects enrolled self-administered the questionnaire and they were able to complete I-IDEA test without any support. In total, 396 (73%) of the 542 healthy controls experienced the DV phenomenon. The frequency of DV was inversely related to age as well as to derealisation, jamais vu, precognitive dreams, depersonalization, paranormal activity, remembering dreams, travel frequency, and daydreams (all < 0.012). The Italian version of IDEA maintains good properties, thus confirming that this instrument is reliable for detecting and characterising the DV phenomenon.
PubMed: 28783090
DOI: 10.3390/bs7030050 -
Acta Neuropathologica Communications Dec 2023Gene fusion events have been linked to oncogenesis in many cancers. However, gene fusions in meningioma are understudied compared to somatic mutations, chromosomal...
Gene fusion events have been linked to oncogenesis in many cancers. However, gene fusions in meningioma are understudied compared to somatic mutations, chromosomal gains/losses, and epigenetic changes. Fusions involving B-raf proto-oncogene, serine/threonine kinase (BRAF) are subtypes of oncogenic BRAF genetic abnormalities that have been reported in certain cases of brain tumors, such as pilocytic astrocytomas. However, BRAF fusions have not been recognized in meningioma. We present the case of an adult female presenting with episodic partial seizures characterized by déjà vu, confusion, and cognitive changes. Brain imaging revealed a cavernous sinus and sphenoid wing mass and she underwent resection. Histopathology revealed a World Health Organization (WHO) grade 1 meningioma. Genetic profiling with next generation sequencing and microarray analysis revealed an in-frame BRAF::PTPRN2 fusion affecting the BRAF kinase domain as well as chromothripsis of chromosome 7q resulting in multiple segmental gains and losses including amplifications of cyclin dependent kinase 6 (CDK6), tyrosine protein-kinase Met (MET), and smoothened (SMO). Elevated pERK staining in tumor cells provided evidence of activated mitogen-activated protein kinase (MAPK) signaling. This report raises the possibility that gene fusion events may be involved in meningioma pathogenesis and warrant further investigation.
Topics: Adult; Female; Humans; Meningeal Neoplasms; Meningioma; Oncogene Proteins, Fusion; Proto-Oncogene Proteins B-raf; Receptor-Like Protein Tyrosine Phosphatases, Class 8
PubMed: 38066633
DOI: 10.1186/s40478-023-01668-w -
Molecular Oncology Sep 2014A major limitation of targeted anticancer therapies is intrinsic or acquired resistance. This review emphasizes similarities in the mechanisms of resistance to endocrine... (Review)
Review
A major limitation of targeted anticancer therapies is intrinsic or acquired resistance. This review emphasizes similarities in the mechanisms of resistance to endocrine therapies in breast cancer and those seen with the new generation of targeted cancer therapeutics. Resistance to single-agent cancer therapeutics is frequently the result of reactivation of the signaling pathway, indicating that a major limitation of targeted agents lies in their inability to fully block the cancer-relevant signaling pathway. The development of mechanism-based combinations of targeted therapies together with non-invasive molecular disease monitoring is a logical way forward to delay and ultimately overcome drug resistance development.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasms; Signal Transduction
PubMed: 24910388
DOI: 10.1016/j.molonc.2014.05.004